2011 marked the 12th year in which the canadian hypertension Education Program (CHEP) released annual guidelines for the diagnosis and treatment of hypertension, and the 6th year that a targeted pharmacist version of these guidelines has been developed. 1 The latest versions of the guidelines emphasize the important role of adherence to both medication and lifestyle strategies. The pharmacist-specific recommendation in the CHEP guidelines indicates: "Health care professional interventions can reduce nonadherence and improve adherence in those who are having problems. Integrating pharmacists into the care of people with hypertension improves blood pressure control." 2 Assessing adherence and intervening when poor adherence is noted are important elements of pharmaceutical care. As pharmacists, we understand the complexity of adherence and the multiple factors that play a role in helping patients initiate and/or maintain a behaviour change, including lifestyle or use of medications. Communication is necessary to identify and understand whether our patients will follow through with the recommended behavioural change, and the relationship that exists between the pharmacist and the patient may play a role in honest communication, thus affecting adherence either positively or negatively. Since adherence to antihypertensives has been shown to decrease hospitalization rates, offsetting medication costs for this chronic condition, 3 it is a vital area for pharmacist involvement.
Adherence assessments do not appear to be done routinely by primary care providers, including pharmacists
Richard and Lussier evaluated the nature and frequency of medication discussions held between primary care physicians and patients and found that medication adherence, possible or observed adverse effects, and shared decision-making about medication use were themes infrequently discussed. 4 Recognizing the importance of communicating about medication-taking behaviour, Bokhour et al. 5 specifically examined how adherence to antihypertensives was assessed during medical encounters with primary care providers. They identified that in 39% of encounters, providers did not ask about medication-taking, and in patients with uncontrolled hypertension, 33% of encounters did not involve questions about medications. 5 These findings are not restricted to physicians. Deschamps and Taylor evaluated the types of discussions that pharmacists have with patients regarding new medications and found that pharmacists consistently informed patients about adverse effects, name, indication and the scheduling of the medication. Notably, discussions about adherence were not even mentioned as an activity that pharmacists perform. Further, on average, pharmacists tended to ask closed-ended questions much more often than open-ended questions, and safety concerns were given more weight than the benefits of the therapy. 6 Given the above findings, an important opportunity exists for pharmacists to use their drug-specific knowledge to identify a patient's level of adherence to antihypertensive drugs, to gain insight on reasons for nonadherence and then to work with the patient to improve medication-taking behaviour.
Assessing and addressing adherence
Reasons cited to explain nonadherent behaviour include 8 :
• Social and economic factors (e.g., cost) • Condition-related factors (e.g., asymptomatic condition and lack of perceived benefit of the intervention) • Therapy-related factors (e.g., adverse effects, real or perceived) • Patient-related factors (e.g., intrinsic beliefs about condition and need to treat) • Health care system/health care team-related factors (e.g., access to care) In order to positively impact adherence, it is essential to first identify nonadherence and the reason(s) for it, before working with the patient collaboratively on solutions. How can we ensure that our patients gain the full benefit of the therapies known to decrease morbidity and mortality? We suggest the following 2-step approach: 1. Identify poor adherence by either:
• Checking refill dates to determine if fills occur regularly and on time. In general, pharmacists should have the ability to initially identify suspected medication nonadherence through profile review. It is also important to verify that the patient uses only your pharmacy for all prescription medications.
• Asking the patient an open-ended question, such as "How many doses of your medication have you missed in the last 2 weeks?" Using open-ended questions has been shown to generate more discussion. 5 2. Create a plan, document and follow-up • When poor adherence is identified, engage in a meaningful dialogue with the patient, in order to understand reasons and to 
Strategies for improving adherence
Strategies that are effective in improving adherence are diverse and most have not been demonstrated to be effective on their own. Reminder packaging has been demonstrated to improve adherence in situations where patients have indicated that forgetfulness is part of the reason for nonadherence. Regular follow-up (defined as every 2 months) in combination with reminder packaging has also been shown to be effective in improving adherence, persistence and blood pressure control, with a decrease in adherence when these 2 services ceased. 9 Similarly, simplifying the treatment regimen through the use of combination and once-daily products has also been shown to increase adherence in hypertensive patients.
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Clinical pearls for assessing adherence
• To prevent poor adherence, ensure that patient education at the initiation of lifestyle changes and/or chronic drug therapy, such as antihypertensives, clearly informs patients that this is lifelong therapy, along with the rationale, which is prevention of cardiovascular morbidity and mortality. Sharing information that informs the patient of the benefit of therapy should outweigh the description of adverse effects.
• If the patient is not interested in adhering to recommended lifestyle changes or drug therapy after discussion about the benefits and risks, then this informed decision should be documented and shared with the primary health care team. Ensure the patient is aware of the consequences of hypertension if untreated.
• Use a survey to collect data from patients in advance of a discussion, if possible. Have patients fill this out independently, perhaps while they are waiting for their prescription(s). One recent Canadian study published in CPJ reported on the use of a medication adherence form, and patients stated that about 66% of the time, this led to an informative discussion about their medications. Notably, pharmacists found that the use of this form did not save them time, but acknowledged that it improved the patient's knowledge of the medication regimen and increased counselling provided to patients.
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• A combination approach for assessing adherence, such as patient self-report, prescription refill rates and an open communication strategy, may have better success than any one method alone.
• When adherence to therapy appears to be good, another common reason for uncontrolled BP is a suboptimal treatment regimen. Intensification of therapy or addition of another agent may be required and should be considered when collaborating with the patient about the care plan. In this case, it would be appropriate to notify the patient's physician that the patient appears to be adherent to therapy and that regimen escalation may be required. 12 • Be practical. You may not be able to assess adherence in every patient, but prioritize those for whom an assessment is warranted, such as patients with uncontrolled BP, those with multiple comorbidities or those who have already suffered a significant blood pressure-related event (stroke, heart attack, renal disease).
• Time management is required. These assessments can be timeconsuming, 11 however, new systems for remuneration, such as those recently unveiled in Ontario, will offer payment for such services.
• Document your conversation, assessment and plan. It's important to let other providers and team members know about the assessment that was done and any plan that was implemented. Documentation is also required to receive remuneration.
Conclusion: Pharmacists should own medication adherence management
Given that nonadherence rates for antihypertensives can be as high as 50% after 2 years, assessing adherence and implementing solutions for the purposes of improving patient outcomes is a valuable and critical patient service. 
